Back to today’s briefing

Story perspectives

Israel Approves New Therapy for High-Risk Neuroblastoma

2/23/2026

43 9 Full Breakdown

Summary

Story summary

Israel approved IWILFIN, a maintenance therapy for high-risk neuroblastoma, for its national health basket.
The decision aims to reduce relapse risk and protect progress from initial treatments.
Neuroblastoma remains underfunded.
Treatment options for relapsed patients are limited.
Advocacy for better access to therapies and sustained investment in research and streamlined pediatric drug approvals are needed to support affected families.

1 of 1

Story summary

Israel approved IWILFIN, a maintenance therapy for high-risk neuroblastoma, for its national health basket.
The decision aims to reduce relapse risk and protect progress from initial treatments.
Neuroblastoma remains underfunded.
Treatment options for relapsed patients are limited.
Advocacy for better access to therapies and sustained investment in research and streamlined pediatric drug approvals are needed to support affected families.